Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Prostate cancer chemotherapy in the era of targeted therapy

Prostate Cancer and Prostatic Diseases volume 12, pages 13–16 (2009)Cite this article

Abstract

Prostate cancer is the most common cancer in men accounting for around 24% of all male cancers in United Kingdom. The role of chemotherapy in the neoadjuvant and adjuvant setting is still unclear despite considerable progress in this area. Chemotherapy for advanced prostate cancer has become the standard of care, however options of treatment following taxotere failure are still limited. This review summarizes recent advances in chemotherapy treatment options for early as well as advanced prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513–1520.

    Article  CAS  PubMed  Google Scholar 

  2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512.

    Article  CAS  PubMed  Google Scholar 

  3. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005; 11: 5233–5240.

    Article  CAS  PubMed  Google Scholar 

  4. Van Poppel H, De Ridder D, Elgamal AA, Van de Voorde W, Werbrouck P, Ackaert K et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian uro-oncological study group. J Urol 1995; 154 (2 Part 1): 429–434.

    CAS  PubMed  Google Scholar 

  5. Hussain M, Smith DC, El-Rayes BF, Du W, Vaishampayan U, Fontana J et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology 2003; 61: 774–780.

    Article  PubMed  Google Scholar 

  6. Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63: 1138–1142.

    Article  PubMed  Google Scholar 

  7. Schmidt JD, Gibbons RP, Murphy GP, Bartolucci A . Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project. Prostate 1996; 28: 51–57.

    Article  CAS  PubMed  Google Scholar 

  8. Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 2007; 177: 1777–1781.

    Article  CAS  PubMed  Google Scholar 

  9. Wosikowski K, Lamphere L, Unteregger G, Jung V, Kaplan F, Xu JP et al. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 2007; 60: 589–600.

    Article  CAS  PubMed  Google Scholar 

  10. Latif T, Wood L, Connell C, Smith DC, Vaughn D, Lebwohl D et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily × 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 2005; 23: 79–84.

    Article  CAS  PubMed  Google Scholar 

  11. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005; 68: 2–9.

    Article  CAS  Google Scholar 

  12. Petrylak DP, Sartor O, Witjes F, Ferrero J, Berry WR, Koletsky A et al. A phase III, randomized, double-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer (HRPC). Prostate Cancer Symp 2007; Abstract 145.

  13. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7: 1429–1437.

    CAS  PubMed  Google Scholar 

  14. Hussain M, Tangen CM, Lara Jr PN, Vaishampayan UN, Petrylak DP, Colevas AD et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005; 23: 8724–8729.

    Article  PubMed  Google Scholar 

  15. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23: 1439–1446.

    Article  CAS  PubMed  Google Scholar 

  16. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson MD, Hussain M, Wilding G et al. Activity of second line chemotherapy in docetaxel-refractory prostate cancer patients: randomised phase II study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110 (3): 556–563.

    Article  CAS  Google Scholar 

  17. Hussain A, Dipaola RS, Baron AD, Higano CS, Tchekmediyan NS, Miller JA et al. A Phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC). J Clin Oncol (Meeting Abstracts) 2004; Abstract 4563.

  18. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21: 679–689.

    Article  CAS  PubMed  Google Scholar 

  19. Vogelzang NJ, Nelson JB, Schulman CC, Dearnaley DP, Saad F, Sleep DJ et al. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. ASCO Annu Meet Proc 2005; 23: 4563.

    Google Scholar 

  20. Picus J, Halabi S, Rini B . The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: Initial results of the CALGB 90006. Proc Am Soc Clin Oncol 2003; 22: 1578.

    Google Scholar 

  21. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2532–2539.

    Article  CAS  PubMed  Google Scholar 

  22. Ning YM, Arlen P, Gulley J, Latham L, Jones E, Chen C et al. A phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol 25, No 18S (June 20 Supplement), 2007: 5114. © 2007 HYPERLINK "http://jco.ascopubs.org/misc/terms.shtml" American Society of Clinical Oncology.

  23. Schröder FH, Wildhagen MF, Erasmus M . ZD1839 (gefitinib) and hormone resistant (HR) prostate cancer—final results of a double blind randomized placebo-controlled phase II study. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol 22, No 14S, (July 15 Supplement), 2004: 4698.

  24. Boccardo F, Rubagotti A, Tacchini L, Lapini A, Cruciani G, De Rubertis G et al. Gefitinib (G) plus prednisone (P) versus placebo (pl) plus prednisone in the treatment of hormone-refractory prostate cancer (HRPC): A randomized phase II trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol 25, No 18S (June 20 Supplement), 2007: 5070.

  25. Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A et al. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol 2007; 59: 581–587.

    Article  CAS  PubMed  Google Scholar 

  26. Lambert JR, Kelly JA, Shim M, Huffer WE, Nordeen SK, Baek SJ et al. Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J Cell Physiol 2006; 208: 566–574.

    Article  CAS  PubMed  Google Scholar 

  27. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D . Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005; 65: 7917–7925.

    Article  CAS  PubMed  Google Scholar 

  28. Nagpal S, Lu J, Boehm MF . Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem 2001; 8: 1661–1679.

    Article  CAS  PubMed  Google Scholar 

  29. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, De Rubertis G et al. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int 2007; 100: 775–779.

    Article  CAS  PubMed  Google Scholar 

  30. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007; 25: 669–674.

    Article  CAS  PubMed  Google Scholar 

  31. Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK . Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J (Sudbury, MA) 2007; 13: 125–129.

    Article  CAS  Google Scholar 

  32. Oh WK, Jacobus S, Ross R, Inman M, Taplin M, Ryan C et al. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy. J Clin Oncol 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol 25, No 18S (June 20 Supplement), 2007: 5156.

Download references

Author information

Authors and Affiliations

  1. Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK

    A Michael & H Pandha

  2. Third Department of Medicine, Oncology Unit, Sotiria General Hospital, Athens University School of Medicine, Athens, Greece

    K Syrigos

Authors
  1. A Michael
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Syrigos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Pandha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Michael.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Michael, A., Syrigos, K. & Pandha, H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis 12, 13–16 (2009). https://doi.org/10.1038/pcan.2008.32

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2008.32

Keywords

This article is cited by

Search

Advanced search

Quick links